Our approach
Our research and development efforts are focused on discovering and developing innovative oncology treatments. Our approach is rooted in scientific excellence and a deep understanding of pancreatic and ovarian cancer.
Therapeutics development
On the horizon, in our laboratories, are several additional investigational drugs, each designed to address different aspects of cancer treatment. From early stage discovery to late-stage clinical trials, we are committed to advancing science and technology to bring new therapies to cancer patients.
Dual inhibition of GSK3B and HDACs reduces cancer cell survival in both human and mouse ovarian cancer cell lines.
To investigate the anti-tumor effect of a newly-developed dual inhibitor (APCS-540) of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs) in ovarian cancer cells.
An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice
Growth, progression, and drug resistance of pancreatic ductal adenocarcinomas (PDACs) have been associated with increased levels and activity of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs). We designed and synthesized molecules that simultaneously inhibit the activities of both enzymes. We tested the effects of one of these molecules, AP-001, in pancreatic cancer cells and mice with pancreatic tumors.